Product/Programme
Preclinical
Phase I
Phase II
Phase III
Key Catalysts
POLB 001
Cancer immunotherapy-induced CRS
Positive data from Phase 1b & in vivo study. Phase 2 enabling activities ongoing. Partnering ready
Oral Encapsulated GLP-1R Agonist
Obesity & diabetes treatment
Proof of technology clinical trial expected to commence H1 2024
Influenza AI Programme
Utilising unique licensed human viral challenge data
Outputs received Q2 2023
Validation in 2024
RSV AI Programme
Utilising unique licensed human viral challenge data
Drug candidates identified and now prioritised following positive outputs from lab-based analysis
- Strategic collaboration with Nasdaq listed company for the development of an optimised oral drug to treat a metabolic condition. Learn more
- €2.3m in non-dilutive grant funding secured to develop a Phase I clinical trial ready oral vaccine candidate; Poolbeg led consortium including AnaBio Technologies, UCD and TCD. Learn more
